** Shares of rare neurological disease-focused pharma company Harmony Biosciences rise HRMY.O 3.5% to $31 premarket
** HRMY posts Q1 adj. profit of 78 cents per share, above analysts' estimate of 58 cents per share - data compiled by LSEG
** Company posts Q1 product revenue of $184.73 million, beating analysts' estimate of $182.9 million
** Company maintains its 2025 product revenue of $820 million to $860 million compared with estimates of $839.89 million
** As of last close, HRMY has fallen 12.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。